{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T20:27:29Z","timestamp":1793219249223,"version":"4.5.0"},"reference-count":102,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","schres-journal.com","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1016\/j.schres.2016.05.015","type":"journal-article","created":{"date-parts":[[2016,6,12]],"date-time":"2016-06-12T03:34:00Z","timestamp":1465702440000},"page":"55-62","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":160,"special_numbering":"C","title":["Treatment of negative symptoms: Where do we stand, and where do we go?"],"prefix":"10.1016","volume":"186","author":[{"given":"Andr\u00e9","family":"Aleman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tania M.","family":"Lincoln","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Bruggeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Melle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Arends","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celso","family":"Arango","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henderikus","family":"Knegtering","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.schres.2016.05.015_bb0005","article-title":"Pomaglumetad methionil (LY2140023 monohydrate) and aripiprazole in patients with schizophrenia: a phase 3, multicenter, double-blind comparison","volume":"758212","author":"Adams","year":"2014","journal-title":"Schizophr. Res. Treat."},{"issue":"2","key":"10.1016\/j.schres.2016.05.015_bb0010","doi-asserted-by":"crossref","first-page":"53","DOI":"10.9758\/cpn.2013.11.2.53","article-title":"Use of repetitive transcranial magnetic stimulation for treatment in psychiatry","volume":"11","author":"Aleman","year":"2013","journal-title":"Clin. Psychopharmacol. Neurosci."},{"issue":"9","key":"10.1016\/j.schres.2016.05.015_bb0015","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1176\/ajp.156.9.1358","article-title":"Memory impairment in schizophrenia: a meta-analysis","volume":"156","author":"Aleman","year":"1999","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2016.05.015_bb0020","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1001\/archpsyc.57.3.270","article-title":"Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-d-aspartate receptor antagonists","volume":"57","author":"Anand","year":"2000","journal-title":"Arch. Gen. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2016.05.015_bb0025","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1097\/00005053-200001000-00010","article-title":"Fluoxetine as an adjunct to conventional antipsychotic treatment of schizophrenia patients with residual symptoms","volume":"188","author":"Arango","year":"2000","journal-title":"J. Nerv. Ment. Dis."},{"issue":"1","key":"10.1016\/j.schres.2016.05.015_bb0030","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.eurpsy.2003.10.004","article-title":"The deficit syndrome in schizophrenia: implications for the treatment of negative symptoms","volume":"19","author":"Arango","year":"2004","journal-title":"Eur. Psychiatry"},{"issue":"2\u20133","key":"10.1016\/j.schres.2016.05.015_bb0035","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.schres.2013.07.026","article-title":"Pharmacological approaches to treating negative symptoms: a review of clinical trials","volume":"150","author":"Arango","year":"2013","journal-title":"Schizophr. Res."},{"issue":"3","key":"10.1016\/j.schres.2016.05.015_bb0040","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1176\/appi.ajp.163.3.488","article-title":"Negative signs and symptoms secondary to antipsychotics: a double-blind, randomized trial of a single dose of placebo, haloperidol, and risperidone in healthy volunteers","volume":"163","author":"Artaloytia","year":"2006","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2016.05.015_bb0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1586\/erp.10.2","article-title":"Subjective tolerability of antipsychotic medications and the emerging science of subjective tolerability disorders","volume":"10","author":"Awad","year":"2010","journal-title":"Expert Rev. Pharmacoecon. Outcomes Res."},{"key":"10.1016\/j.schres.2016.05.015_bb0050","series-title":"Schizophrenia. Cognitive Theory, Research and Therapy","author":"Beck","year":"2009"},{"key":"10.1016\/j.schres.2016.05.015_bb0055","series-title":"A Step-by-Step Guide","article-title":"Social skills training for schizophrenia","author":"Bellack","year":"1997"},{"key":"10.1016\/j.schres.2016.05.015_bb0060","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1080\/17522430903505966","article-title":"Motivation and avolition in schizophrenia patients: the role of self-efficacy","volume":"2","author":"Bentall","year":"2010","journal-title":"Psychosis"},{"issue":"3","key":"10.1016\/j.schres.2016.05.015_bb0065","doi-asserted-by":"crossref","first-page":"280","DOI":"10.4088\/JCP.08m04250yel","article-title":"Prevalence of negative symptoms in outpatients with schizophrenia spectrum disorders treated with antipsychotics in routine clinical practice: findings from the CLAMORS study","volume":"71","author":"Bobes","year":"2010","journal-title":"J. Clin. Psychiatry"},{"issue":"7","key":"10.1016\/j.schres.2016.05.015_bb0070","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1176\/appi.ajp.2012.11071091","article-title":"Examining transcranial direct-current stimulation (tDCS) as a treatment for hallucinations in schizophrenia","volume":"169","author":"Brunelin","year":"2012","journal-title":"Am. J. Psychiatry"},{"issue":"6","key":"10.1016\/j.schres.2016.05.015_bb0075","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1176\/ajp.155.6.751","article-title":"Positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndrome","volume":"155","author":"Buchanan","year":"1998","journal-title":"Am. J. Psychiatry"},{"issue":"10","key":"10.1016\/j.schres.2016.05.015_bb0080","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1176\/appi.ajp.2007.06081358","article-title":"The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments","volume":"164","author":"Buchanan","year":"2007","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2016.05.015_bb2000","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/JCP.0b013e31823f880a","article-title":"Asenapine versus olanzapine in people with persistent negative symptoms of schizophrenia","volume":"32","author":"Buchanan","year":"2012","journal-title":"J. Clin. Psychopharmacol."},{"issue":"4","key":"10.1016\/j.schres.2016.05.015_bb0085","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1093\/schbul\/sbu151","article-title":"Rasagiline in the treatment of the persistent negative symptoms of schizophrenia","volume":"41","author":"Buchanan","year":"2015","journal-title":"Schizophr. Bull."},{"issue":"7","key":"10.1016\/j.schres.2016.05.015_bb0090","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.euroneuro.2014.03.007","article-title":"A phase II\/III trial of bitopertin monotherapy compared with placebo in patients with an acute exacerbation of schizophrenia - results from the CandleLyte study","volume":"24","author":"Bugarski-Kirola","year":"2014","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.schres.2016.05.015_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.schres.2014.01.016","article-title":"d-Cycloserine augmentation of cognitive remediation in schizophrenia","author":"Cain","year":"2014","journal-title":"Schizophr. Res."},{"issue":"6","key":"10.1016\/j.schres.2016.05.015_bb0100","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.jaac.2014.04.004","article-title":"Intervention for adolescents with early-onset psychosis and their families: a randomized controlled trial","volume":"53","author":"Calvo","year":"2014","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"issue":"3","key":"10.1016\/j.schres.2016.05.015_bb0105","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1002\/da.22335","article-title":"Theta-burst stimulation: a new form of TMS treatment for depression?","volume":"32","author":"Chung","year":"2015","journal-title":"Depress. Anxiety"},{"issue":"1\u20133","key":"10.1016\/j.schres.2016.05.015_bb0110","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.schres.2016.02.011","article-title":"Do we need oxytocin to treat schizophrenia? A randomized clinical trial","volume":"172","author":"Dagani","year":"2016","journal-title":"Schizophr. Res."},{"issue":"3","key":"10.1016\/j.schres.2016.05.015_bb0115","doi-asserted-by":"crossref","DOI":"10.1093\/ijnp\/pyv105","article-title":"Cortico-striatal GABAergic and glutamatergic dysregulations in subjects at ultra-high risk for psychosis investigated with proton magnetic resonance spectroscopy","volume":"19","author":"de la Fuente-Sandoval","year":"2015","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"10","key":"10.1016\/j.schres.2016.05.015_bb0120","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.4088\/JCP.08m04935gry","article-title":"Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine add-on therapy to clozapine","volume":"70","author":"De Lucena","year":"2009","journal-title":"J. Clin. Psychiatry"},{"issue":"1\u20133","key":"10.1016\/j.schres.2016.05.015_bb0125","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.schres.2010.08.015","article-title":"Safety and proof of principle study of cerebellar vermal theta burst stimulation in refractory schizophrenia","volume":"124","author":"Demirtas-Tatlidede","year":"2010","journal-title":"Schizophr. Res."},{"issue":"0","key":"10.1016\/j.schres.2016.05.015_bb0130","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.schres.2013.05.023","article-title":"Targeting alpha-7 nicotinic neurotransmission in schizophrenia: a novel agonist strategy","volume":"148","author":"Deutsch","year":"2013","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2016.05.015_bb0135","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1093\/schbul\/21.4.631","article-title":"Family interventions for schizophrenia","volume":"21","author":"Dixon","year":"1995","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2016.05.015_bb0140","doi-asserted-by":"crossref","first-page":"411","DOI":"10.4088\/JCP.08r04808yel","article-title":"Repetitive transcranial magnetic stimulation for negative symptoms of schizophrenia: review and meta-analysis","volume":"71","author":"Dlabac-de Lange","year":"2010","journal-title":"J. Clin. Psychiatry"},{"issue":"6","key":"10.1016\/j.schres.2016.05.015_bb0145","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1017\/S0033291714002360","article-title":"Efficacy of bilateral repetitive transcranial magnetic stimulation for negative symptoms of schizophrenia: results of a multicenter double-blind randomized controlled trial","volume":"45","author":"Dlabac-de Lange","year":"2015","journal-title":"Psychol. Med."},{"key":"10.1016\/j.schres.2016.05.015_bb0150","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1093\/schbul\/sbv161","article-title":"Self-evaluation of negative symptoms: a novel tool to assess negative symptoms","volume":"42","author":"Dollfus","year":"2016","journal-title":"Schizophr. Bull."},{"issue":"1","key":"10.1016\/j.schres.2016.05.015_bb2100","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1037\/a0014415","article-title":"Are psychotic psychopathology and neurocognition orthogonal? A systematic review of their associations","volume":"135","author":"Dominguez Mde","year":"2009","journal-title":"Psychol. Bull."},{"key":"10.1016\/j.schres.2016.05.015_bb0155","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1093\/schbul\/sbv121","article-title":"Transcranial magnetic stimulation for schizophrenia","volume":"41","author":"Dougall","year":"2015","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2016.05.015_bb0160","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1176\/appi.ps.51.4.513","article-title":"Management of negative symptoms among patients with schizophrenia attending multiple-family groups","volume":"51","author":"Dyck","year":"2000","journal-title":"Psychiatr. Serv."},{"key":"10.1016\/j.schres.2016.05.015_bb0165","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.psychres.2013.03.020","article-title":"Negative symptom improvement during cognitive rehabilitation. Results from a two-year trial of cognitive enhancement therapy","volume":"209","author":"Eak","year":"2013","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.schres.2016.05.015_bb0170","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.cpr.2013.07.001","article-title":"Psychosocial treatments for negative symptoms in schizophrenia: current practices and future directions","volume":"33","author":"Elis","year":"2013","journal-title":"Clin. Psychol. Rev."},{"key":"10.1016\/j.schres.2016.05.015_bb0175","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1176\/appi.ajp.157.5.826","article-title":"Placebo-controlled trial of glycine added to clozapine in schizophrenia","volume":"157","author":"Evins","year":"2000","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2016.05.015_bb0180","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1744-6163.2010.00255.x","article-title":"Anticipatory pleasure skills training: a new intervention to reduce anhedonia in schizophrenia","volume":"46","author":"Favrod","year":"2010","journal-title":"Perspect. Psychiatr. Care"},{"issue":"3","key":"10.1016\/j.schres.2016.05.015_bb0185","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.biopsych.2015.07.025","article-title":"A review of oxytocin's effects on the positive, negative, and cognitive domains of schizophrenia","volume":"79","author":"Feifel","year":"2016","journal-title":"Biol. Psychiatry"},{"issue":"6","key":"10.1016\/j.schres.2016.05.015_bb0190","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1038\/npp.2015.3","article-title":"Antipsychotics and amotivation","volume":"40","author":"Fervaha","year":"2015","journal-title":"Neuropsychopharmacology"},{"issue":"6","key":"10.1016\/j.schres.2016.05.015_bb0195","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.brs.2014.08.002","article-title":"A negative pilot study of daily bimodal transcranial direct current stimulation in schizophrenia","volume":"7","author":"Fitzgerald","year":"2014","journal-title":"Brain Stimul."},{"issue":"2","key":"10.1016\/j.schres.2016.05.015_bb0200","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1177\/0269881114562092","article-title":"Dissecting negative symptoms in schizophrenia: opportunities for translation into new treatments","volume":"29","author":"Foussias","year":"2015","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.schres.2016.05.015_bb0205","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.schres.2008.11.027","article-title":"Meta-analysis of the effects of repetitive transcranial magnetic stimulation (rTMS) on negative and positive symptoms in schizophrenia","volume":"108","author":"Freitas","year":"2009","journal-title":"Schizophr. Res."},{"issue":"4","key":"10.1016\/j.schres.2016.05.015_bb0210","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1093\/schbul\/sbu170","article-title":"Treatments of negative symptoms in schizophrenia: meta-analysis of 168 randomized placebo-controlled trials","volume":"41","author":"Fusar-Poli","year":"2015","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2016.05.015_bb0215","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1017\/S0033291709006126","article-title":"Efficacy and effectiveness of individual family intervention on social and clinical functioning and family burden in severe schizophrenia: a 2-year randomized controlled study","volume":"40","author":"Giron","year":"2010","journal-title":"Psychol. Med."},{"key":"10.1016\/j.schres.2016.05.015_bb0220","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1001\/jamapsychiatry.2014.257","article-title":"Bitopertin: the good news and bad news","volume":"71","author":"Goff","year":"2014","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.schres.2016.05.015_bb0225","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.psychres.2010.01.005","article-title":"Asocial beliefs as predictors of asocial behavior in schizophrenia","volume":"177","author":"Grant","year":"2010","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.schres.2016.05.015_bb0230","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1001\/archgenpsychiatry.2011.129","article-title":"Randomized trial to evaluate the efficacy of cognitive therapy for low-functioning patients with schizophrenia","volume":"69","author":"Grant","year":"2012","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.schres.2016.05.015_bb0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.schres.2015.04.002","article-title":"Sex hormones and oxytocin augmentation strategies in schizophrenia: a quantitative review","author":"Heringa","year":"2015","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2016.05.015_bb0240","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1001\/archpsyc.1986.01800070019003","article-title":"Family psychoeducation, social skills training, and maintenance chemotherapy in the aftercare treatment of schizophrenia: I. one-year effects of a controlled study on relapse and expressed emotion","volume":"43","author":"Hogarty","year":"1986","journal-title":"Arch. Gen. Psychiatry"},{"issue":"9","key":"10.1016\/j.schres.2016.05.015_bb0245","first-page":"627","article-title":"Pharmacological treatment of negative symptoms in schizophrenia; research and practice. [Medicamenteuze interventie bij negatieve symptomen bij patienten met schizofrenie]","volume":"52","author":"Jiawan","year":"2010","journal-title":"Tijdschr. Psychiatrie"},{"issue":"6","key":"10.1016\/j.schres.2016.05.015_bb0250","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1055\/s-0034-1385931","article-title":"Off-label use of memantine as adjunctive treatment in schizophrenia: a retrospective case series study","volume":"47","author":"John","year":"2014","journal-title":"Pharmacopsychiatry"},{"issue":"2","key":"10.1016\/j.schres.2016.05.015_bb0255","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr. Bull."},{"issue":"5","key":"10.1016\/j.schres.2016.05.015_bb0260","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1001\/archgenpsychiatry.2011.1519","article-title":"Elevated prefrontal cortex \u03b3-aminobutyric acid and glutamate-glutamine levels in schizophrenia measured in vivo with proton magnetic resonance spectroscopy","volume":"69","author":"Kegeles","year":"2012","journal-title":"Arch. Gen. Psychiatry"},{"issue":"1\u20133","key":"10.1016\/j.schres.2016.05.015_bb0265","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.schres.2011.08.005","article-title":"Adjunct minocycline to clozapine treated patients with persistent schizophrenia symptoms","volume":"133","author":"Kelly","year":"2011","journal-title":"Schizophr. Res."},{"issue":"4","key":"10.1016\/j.schres.2016.05.015_bb0270","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1097\/JCP.0000000000000345","article-title":"Adjunctive minocycline in clozapine-treated schizophrenia patients with persistent symptoms","volume":"35","author":"Kelly","year":"2015","journal-title":"J. Clin. Psychopharmacol."},{"issue":"3","key":"10.1016\/j.schres.2016.05.015_bb0275","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/JCP.0b013e318218dcd5","article-title":"A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia","volume":"31","author":"Kinon","year":"2011","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.schres.2016.05.015_bb0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopsych.2015.03.016","article-title":"Exploratory analysis for a targeted patient population responsive to the metabotropic glutamate 2\/3 receptor agonist pomaglumetad methionil in schizophrenia","author":"Kinon","year":"2015","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.schres.2016.05.015_bb0285","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1093\/schbul\/sbj053","article-title":"The NIMH-MATRICS consensus statement on negative symptoms","volume":"32","author":"Kirkpatrick","year":"2006","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2016.05.015_bb2200","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.schres.2016.05.003","article-title":"Secondary negative symptoms \u2013 a review of mechanisms, assessment and treatment","volume":"186","author":"Kirschner","year":"2017","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2016.05.015_bb0290","doi-asserted-by":"crossref","first-page":"S98","DOI":"10.1093\/schbul\/sbr073","article-title":"Negative symptoms of schizophrenia as primary target of cognitive behavioral therapy: results of the randomized clinical TONES study","volume":"37","author":"Klingberg","year":"2011","journal-title":"Schizophr. Bull."},{"issue":"2","key":"10.1016\/j.schres.2016.05.015_bb0295","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1176\/appi.ajp.2012.12010109","article-title":"The Clinical Assessment Interview for Negative Symptoms (CAINS): final development and validation","volume":"170","author":"Kring","year":"2013","journal-title":"Am. J. Psychiatry"},{"issue":"11","key":"10.1016\/j.schres.2016.05.015_bb0300","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.biopsych.2015.08.017","article-title":"Toward illness phase-specific pharmacotherapy for schizophrenia","volume":"78","author":"Krystal","year":"2015","journal-title":"Biol. Psychiatry"},{"issue":"11","key":"10.1016\/j.schres.2016.05.015_bb0305","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1001\/archpsyc.62.11.1196","article-title":"Sarcosine or d-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study","volume":"62","author":"Lane","year":"2005","journal-title":"Arch. Gen. Psychiatry"},{"issue":"5","key":"10.1016\/j.schres.2016.05.015_bb0310","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/j.1600-0447.2006.00887.x","article-title":"The treatment of negative symptoms and deficit states of chronic schizophrenia: olanzapine compared to amisulpride and placebo in a 6-month double-blind controlled clinical trial","volume":"114","author":"Lecrubier","year":"2006","journal-title":"Acta Psychiatr. Scand."},{"issue":"9657","key":"10.1016\/j.schres.2016.05.015_bb0315","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(08)61764-X","article-title":"Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis","volume":"373","author":"Leucht","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.schres.2016.05.015_bb0320","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.psychres.2016.04.046","article-title":"Delayed effect of repetitive transcranial magnetic stimulation (rTMS) on negative symptoms of schizophrenia: findings from a randomized controlled trial","volume":"240","author":"Li","year":"2016","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.schres.2016.05.015_bb0325","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.jpsychires.2013.01.024","article-title":"Two subdomains of negative symptoms in psychotic disorders: established and confirmed in two large cohorts","volume":"47","author":"Liemburg","year":"2013","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.schres.2016.05.015_bb0330","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1093\/schbul\/sbr066","article-title":"Negative symptoms and social cognition. Detecting suitable targets for psychological interventions","volume":"37","author":"Lincoln","year":"2011","journal-title":"Schizophr. Bull."},{"issue":"2\u20133","key":"10.1016\/j.schres.2016.05.015_bb0335","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.schres.2013.03.019","article-title":"A systematic review of psychostimulant treatment of negative symptoms of schizophrenia: challenges and therapeutic opportunities","volume":"147","author":"Lindenmayer","year":"2013","journal-title":"Schizophr. Res."},{"issue":"1\u20133","key":"10.1016\/j.schres.2016.05.015_bb0340","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.schres.2014.01.011","article-title":"Minocycline supplementation for treatment of negative symptoms in early-phase schizophrenia: a double blind, randomized, controlled trial","volume":"153","author":"Liu","year":"2014","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2016.05.015_bb0345","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1477-7525-2-15","article-title":"Social function in schizophrenia and schizoaffective disorder: associations with personality, symptoms and neurocognition","volume":"2","author":"Lysaker","year":"2004","journal-title":"Health Qual. Life Outcomes"},{"issue":"7","key":"10.1016\/j.schres.2016.05.015_bb0350","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s00406-015-0596-y","article-title":"Pharmacological treatment of negative symptoms in schizophrenia","volume":"265","author":"M\u00f6ller","year":"2015","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"issue":"1","key":"10.1016\/j.schres.2016.05.015_bb0355","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/BF02191543","article-title":"A path-analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients. A re-evaluation of the North American risperidone study","volume":"245","author":"M\u00f6ller","year":"1995","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.schres.2016.05.015_bb2600","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.schres.2016.05.014","article-title":"Primary and persistent negative symptoms: concepts, assessments and neurobiological bases","volume":"186","author":"Mucci","year":"2017","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2016.05.015_bb0360","author":"NICE"},{"issue":"5","key":"10.1016\/j.schres.2016.05.015_bb0365","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/hup.2426","article-title":"Efficacy and tolerability of minocycline augmentation therapy in schizophrenia: a systematic review and meta- analysis of randomized controlled trials","volume":"29","author":"Oya","year":"2014","journal-title":"Hum. Psychopharmacol."},{"key":"10.1016\/j.schres.2016.05.015_bb0370","series-title":"Case Reports in Psychiatry, 2014","first-page":"384783","article-title":"Tackling negative symptoms of schizophrenia with memantine","author":"Paraschakis","year":"2014"},{"issue":"9","key":"10.1016\/j.schres.2016.05.015_bb0375","doi-asserted-by":"crossref","first-page":"e007619","DOI":"10.1136\/bmjopen-2015-007619","article-title":"Negative symptoms in schizophrenia: a study in a large clinical sample of patients using a novel automated method","volume":"5","author":"Patel","year":"2015","journal-title":"BMJ Open"},{"issue":"5","key":"10.1016\/j.schres.2016.05.015_bb0380","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1080\/09602011.2011.557292","article-title":"Transcranial electrical stimulation (tES - tDCS; tRNS, tACS) methods","volume":"21","author":"Paulus","year":"2011","journal-title":"Neuropsychol. Rehabil."},{"issue":"4","key":"10.1016\/j.schres.2016.05.015_bb0385","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.brs.2009.02.004","article-title":"Repetitive transcranial magnetic stimulation or transcranial direct current stimulation?","volume":"2","author":"Priori","year":"2009","journal-title":"Brain Stimul."},{"issue":"12","key":"10.1016\/j.schres.2016.05.015_bb0390","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1001\/jamapsychiatry.2015.2196","article-title":"Ventral striatal activation during reward processing in psychosis: a neurofunctional meta-analysis","volume":"72","author":"Radua","year":"2015","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.schres.2016.05.015_bb0395","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1093\/schbul\/sbl021","article-title":"Integrated psychological therapy (IPT) for schizophrenia: is it effective?","volume":"32","author":"Roder","year":"2006","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2016.05.015_bb0400","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.psychres.2013.12.019","article-title":"Revisiting the therapeutic effect of rTMS on negative symptoms in schizophrenia: a meta-analysis","volume":"215","author":"Shi","year":"2014","journal-title":"Psychiatry Res."},{"issue":"10","key":"10.1016\/j.schres.2016.05.015_bb0405","doi-asserted-by":"crossref","first-page":"859","DOI":"10.2165\/11586650-000000000-00000","article-title":"Meta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophrenia","volume":"25","author":"Singh","year":"2011","journal-title":"CNS Drugs"},{"issue":"3","key":"10.1016\/j.schres.2016.05.015_bb0410","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1192\/bjp.bp.109.067710","article-title":"Efficacy of antidepressants in treating the negative symptoms of chronic schizophrenia: meta-analysis","volume":"197","author":"Singh","year":"2010","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.schres.2016.05.015_bb0415","article-title":"Effects of transcranial direct current stimulation (tDCS) on cognition, symptoms, and smoking in schizophrenia: a randomized controlled study","volume":"16","author":"Smith","year":"2015","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2016.05.015_bb0420","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.jbtep.2013.01.004","article-title":"Cognitive Behavioral Therapy for negative symptoms (CBT-n) in psychotic disorders: a pilot study","volume":"44","author":"Staring","year":"2013","journal-title":"J. Behav. Ther. Exp. Psychiatry"},{"issue":"2\u20133","key":"10.1016\/j.schres.2016.05.015_bb0425","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.schres.2013.08.020","article-title":"Pomaglumetad methionil: no significant difference as an adjunctive treatment for patients with prominent negative symptoms of schizophrenia compared to placebo","volume":"150","author":"Stauffer","year":"2013","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2016.05.015_bb2300","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.neuropharm.2013.04.038","article-title":"Prosocial effects of oxytocin in two mouse models of autism spectrum disorders","volume":"72","author":"Teng","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.schres.2016.05.015_bb0430","doi-asserted-by":"crossref","DOI":"10.1093\/ijnp\/pyv049","article-title":"Randomized controlled trials of add-on antidepressants in schizophrenia","author":"Terevnikov","year":"2015","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.schres.2016.05.015_bb0435","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.schres.2009.01.002","article-title":"The efficacy of lamotrigine in clozapine-resistant schizophrenia: a systematic review and meta-analysis","volume":"109","author":"Tiihonen","year":"2009","journal-title":"Schizophr. Res."},{"issue":"2\u20133","key":"10.1016\/j.schres.2016.05.015_bb0445","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.schres.2004.05.005","article-title":"Glutamatergic drugs for schizophrenia: a systematic review and meta-analysis","volume":"72","author":"Tuominen","year":"2005","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2016.05.015_bb0450","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1176\/appi.ajp.2013.13081159","article-title":"Psychological interventions for psychosis: a meta-analysis of comparative outcome studies","volume":"171","author":"Turner","year":"2014","journal-title":"Am. J. Psychiatr."},{"issue":"6","key":"10.1016\/j.schres.2016.05.015_bb0455","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1055\/s-0034-1383656","article-title":"Clozapine augmented with glutamate modulators in refractory schizophrenia: a review and metaanalysis","volume":"47","author":"Veerman","year":"2014","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.schres.2016.05.015_bb0460","first-page":"1","article-title":"Memantine augmentation in clozapine-refractory schizophrenia: a randomized, double-blind, placebo-controlled crossover study","volume":"6","author":"Veerman","year":"2016","journal-title":"Psychol. Med."},{"key":"10.1016\/j.schres.2016.05.015_bb0465","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.schres.2015.04.008","article-title":"A randomized pilot study of MOtiVation and Enhancement (MOVE) Training for negative symptoms in schizophrenia","volume":"165","author":"Velligan","year":"2015","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2016.05.015_bb0470","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1017\/S0033291714001147","article-title":"Adapted cognitive\u2013behavioural therapy required for targeting negative symptoms in schizophrenia: meta-analysis and meta-regression","volume":"45","author":"Velthorst","year":"2015","journal-title":"Psychol. Med."},{"key":"10.1016\/j.schres.2016.05.015_bb0475","first-page":"1","article-title":"Meta-analysis of efficacy of mirtazapine as an adjunctive treatment of negative symptoms in schizophrenia","author":"Vidal","year":"2013","journal-title":"Clin. Schizophr. Relat. Psychoses"},{"issue":"2","key":"10.1016\/j.schres.2016.05.015_bb0480","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1093\/schbul\/sbv072","article-title":"Phase 2 trial of an alpha-7 nicotinic receptor agonist (TC-5619) in negative and cognitive symptoms of schizophrenia","volume":"42","author":"Walling","year":"2016","journal-title":"Schizophr. Bull."},{"issue":"11","key":"10.1016\/j.schres.2016.05.015_bb0485","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.biopsych.2014.10.009","article-title":"Left prefrontal high-frequency repetitive transcranial magnetic stimulation for the treatment of schizophrenia with predominant negative symptoms: a sham-controlled, randomized multicenter trial","volume":"77","author":"Wobrock","year":"2015","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.schres.2016.05.015_bb0490","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1093\/schbul\/sbm114","article-title":"Cognitive behavior therapy for schizophrenia: effect sizes, clinical models, and methodological rigor","volume":"34","author":"Wykes","year":"2008","journal-title":"Schizophr. Bull."}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996416302390?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996416302390?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T21:29:50Z","timestamp":1748986190000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996416302390"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":102,"alternative-id":["S0920996416302390"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2016.05.015","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of negative symptoms: Where do we stand, and where do we go?","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2016.05.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}